Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Orthogon Therapeutics raises $11M in a funding round for its BK virus antiviral drug program, bringing total funding to $36M.
Amount Raised
$11 Million
Round Type
Funding Round
CantonInformation TechnologyBiotechnologyHealth CareScience And EngineeringDescription
Orthogon Therapeutics has completed a follow-on financing of $11 million to further advance its first-in-class drug against BK polyomavirus. This funding aims to support the development of an innovative oral therapy targeting viral proteins. BK virus infections are particularly problematic for transplant patients, where approved treatments are lacking. The new funding will help to address these urgent clinical needs.
Fundz sees it the moment Orthogon Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Orthogon Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.